Use of Antiplatelet Agents for Primary and Secondary Prevention of Cardiovascular Disease Amongst Type 2 Diabetic Patients

Abstract

Background. A retrospective observational study was conducted to study the use of antiplatelet agents for primary and secondary prevention of cardiovascular disease among hospitalized type 2 diabetes mellitus patients.

Method. A total of 355 patients were included in the study. The compliance with the American Diabetes Association recommendation on the use of antiplatelet therapy for prevention of cardiovascular disease was studied.

Results. For the primary prevention group, type 2 diabetes mellitus, patients with known dyslipidemia were more likely to receive antiplatelet therapy than those without dyslipidemia (P = 0.023). The rate of adherence to the American Diabetes Association recommendations on the use of antiplatelet therapy for secondary prevention of cardiovascular disease was higher than for primary prevention of cardiovascular disease (P = 0.001).

Conclusion. In conclusion, many of the eligible patients still do not receive antiplatelet therapy, particularly in primary prevention of cardiovascular disease. Measures should be taken to ensure that type 2 diabetes mellitus patients receive the antiplatelet therapy and hence prevent macrovascular complications.

Keywords

Type 2 diabetes primary secondary prevention cardiovascular disease antiplatelet

Get full access to this article

View all access options for this article.

References

Public Health Institute. Second National Health and Morbidity Survey-Diabetes. Available at: http://www.diabetes.org.my/DiabMalaysia.htm. Accessed August 28, 2006.

King H. , Aubert RE , Herman WH Global burden of diabetes, 1995-2025. Diabetes Care . 1998;21:1414-1431.

Utusan Malaysia Online 30 April 2007. Kawalan diabetes di kalangan pesakit muda tidak memuaskan . Available at: http://www.utusan.com.my . Accessed September 24, 2007.

World Health Organization. Mortality Country Fact Sheet 2006. Available at: http://www.who.int/whosis/mort/profiles/mort_wpro_mys_malaysia.pdf. Accessed September 24, 2007.

Koskinen SV , Reunanen AR , Martelin TP , Valkonen T. Mortality in a large population-based cohort of patients with drug-treated diabetes mellitus. Am J Publ Health. 1998;88:765-770.

Clinical Practice Guidelines. Management of Type 2 Diabetes Mellitus. Malaysia: Ministry of Health Malaysia, Persatuan Diabetes Malaysia, Academy of Medicine ; 2004:31.

Thompson DM Cardiovascular disease and diabetes. BC Endocrine Research Foundation Newsletter. 1999;1:3.

Klinke JA , Johnson JA , Guirguis LM , et al. Underuse of aspirin in type 2 diabetes mellitus: prevalence and correlates of therapy in rural Canada. Clin Ther (The International Peer-Reviewed Journal of Drug Therapy). 2004 ;26:439-446.

Antithrombotic Trialists ' Collaboration. Collaborative meta-analysis of infarction, and stroke in high risk patients. Br Med J . 2002;324:71-86.

10.

Colwell JA , Nesto RW The platelet in diabetes. Diabetes Care. 2003 ;26:2181-2188.

11.

American Diabetes Association. Standards of medical care in diabetes . Diabetes Care. 2006;29:4-42.

12.

International Diabetes Federation. Global Guideline for Type 2 Diabetes. 2005. Available at: http://www.idf.org/webdata/docs/IDFGGT2D.pdf. Accessed August 18, 2006.

13.

Canada Diabetes Association. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2003;27:1-152.

14.

Malaysia Diabetes Association. Practice Guideline for Diabetes Mellitus Type2 (IMDDM). 1996 . Available at: http://www.diabetes.org.my/csusframe.htm . Accessed August 18, 2006.

15.

Meigs JB , Stafford RS Cardiovascular disease prevention practices by US physicians for patients with diabetes. J Gen Intern Med. 2000;15:220-228.

16.

Bruno A. , Grassi G. , Dani F. , Degiovanni M. , Maghenzani G. , Pagano G. Use of antiplatelet therapy in a diabetes outpatient service of a large urban public hospital. Nutr Metabol Cardiovasc Dis. 2004;15:42-46.

17.

Colwell JA Aspirin therapy in diabetes. Diabetes Care. 2004;20:1767-1771.

18.

Wild S. , Roglic G. , Green A. , Sicree R. , King H. Global prevalence of diabetes. Diabetes Care. 2004;27:1047-1053.

19.

Ng TP , Goh LG , Tan Y. , et al. Ethnic differences in glycemic control in adults type 2 diabetic patients in primary care: a 3 year follow up study. Diabet Med. 2005;22:1598-1604.

20.

Malaysia Medical Association. Diabetes in Malaysia: Problem and Challenges. 2002. Available at: http://www.mma.org.my/info/1_diabetes_90.htm. Accessed January 18, 2006.

21.

Kempler P. Learning from large cardiovascular clinical trials: classical cardiovascular risk factors. Diabetes Res Clin Pract. 2005 ;68:43-47.

22.

Haffner SM , Lehto S. , Ronnemaa T. , Pyorala K. , Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.

23.

Cull CA , Neil Haw , Holman RR Changing aspirin use in patients with type 2 diabetes in the UKPDS . Diabet Med. 2004;21:1368-1371.

24.

Rolka DB , Fagot-Campagna A. , Narayan KM Aspirin use among adults with diabetes:estimates from Third National Health and Nutrition Examination Survey. Diabetes Care. 2001;24:197-201.

25.

Miller SR , Littenberg B. , Maclean CD Prevalence of antiplatelet therapy in patients with diabetes. Cardiol Diabetol. 2005;4. Available at: Bio Med Central database. Accessed August 23, 2006.

26.

Hayden M. , Pignone M. , Philips C. , Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for U.S Preventive Services Task Forces. Ann Intern Med. 2002;136:161-172.

27.

Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians' health study. New Engl J Med. 1989;321:129-135.

28.

Collaborative Group of the Primary Preventive Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet. 2001;357:89-95.

29.

Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke in high risk patients . Br Med J. 1994;308:81-104.

30.

TIMAD Study Group. Ticlopidine treatment reduces the progression of non-proliferative diabetes retinopathy. Arch Ophthamol. 1990;108:1577-1583.

31.

Drug Formulary University Malaya Medical Centre. Senarai Ubat-Ubatan 2005. Malaysia : University Malaya Medical Centre; 2005.

32.

Patrono C. , Bachmann F. , Baigent C. , et al. Expert consensus document on the use of antiplatelet agents . Eur Heart J. 2004;25:166-181.

33.

Yudkin JS Which diabetic patients should be taking aspirin? Those with vascular disease and those at greatly increased risk of vascular disease. Br Med J. 1995;311:641-642.

34.

Hansson L. , Zanchetti A. , Carruthers SG , et al. The HOT study group: effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet . 1998;351:1755-1762.

35.

Etdrs Investigators . Aspirin effects on morbidity and mortality in patients with diabetes mellitus. JAMA. 1992 ;268:1292-1300.

36.

Nguyen KX , Marinac JS , Chao S. Aspirin for primary prevention in patients with diabetes mellitus. Fam Med. 2005;37:112-117.

37.

McFarlane SI , Jacober SJ , Winer N. , et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers . Diabetes Care. 2002;25:718-723.

38.

Sacco M. , Pellegrini F. , Roncaglioni MC , Avanzini F. , Tognoni G. , Nicolucci A. ; PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the primary prevention project (PPP) trial. Diabetes Care. 2003;26:3264-3272.

39.

Mogensen CE Natural history of cardiovascular and renal disease in patients with type 2 diabetes: effect of therapeutic interventions and risk modifications . Am J Cardiol. 1998;82:4-8.

40.

Augustovski FA , Cantor SB , Thach CT , Spann SJ Aspirin for primary prevention of cardiovascular events. J Gen Intern Med. 1998;13:824-835.

41.

Rang HP , Dale MM , Ritter JM , Moore PK Pharmacology. 5th ed. London : Churchill Livingstone; 2003.

42.

Brown LC , Johnson JA , Majumdar SR , Tsuyuki RT , McAlister FA Evidence of suboptimum management of cardiovascular risk patients with type 2 diabetes mellitus and symtompatic atherosclerosis. Can Med Assoc J. 2004;171:1189-1192.

43.

Morimoto T. , Fukui T. , Lee TH Application of US guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. Am J Med. 2004;117:459-468.